Established in 1998, Trichem has evolved as an Active Pharmaceutical Ingredients and Intermediate sourcing company for regulated and non-regulated markets. At Trichem LifeScience, we have committed to support the truly global effort to fight the COVID-19 pandemic across multiple fronts. The need for an urgent response to the virus has challenged pharmaceutical industry and limited the capacity of vaccine production. Global pharmaceutical supply chains have repeatedly proved incapable of serving people in all regions of the world in a timely manner that would prevent needless loss of life. During the COVID-19 pandemic, 1·3 billion people living in Africa were not factored into pharmaceutical companies’ global supply management planning. A more practical approach is globally distributed manufacturing operations serving different regions of the world. There is the urgent need for the rapid manufacture of vaccines has required a different approach during the pandemic. Led by a global team, we are changing how we produce and manufacture a vaccine at scale and pace.
This robust pandemic response has seen our manufacturing and supply chain experts, engineers, technical scientists and Quality professionals work to rapidly apply innovative thinking to commercial vaccine production.
Our vaccines after being approved by regulators will be available to support broad and equitable access. To produce billions of doses of a potential vaccine for markets around the world, we are building regional supply chains to provide rapid access to as many countries as possible, as quickly as possible following regulatory approval, while reducing transportation and any potential export or importation constraints. This network was designed with our broad understanding of global supplier capabilities, combined with a focus on local manufacturing where possible and a drive to balance speed of supply with affordable costs. To accelerate vaccine production and supply involves collaboration with more than 10 supply partners in 5 countries, supported by modern analytical testing sites. These partners will collaborate with us throughout the entire manufacturing process, receiving support and technical guidance.
Central to our mass supply capability is defining the manufacturing and controls (CMC) of the production process. During CMC, we are developing an optimised, repeatable manufacturing process that delivers maximum yields and ensures high-quality product across our supply chain. In the meantime, our procurement team is working to secure and accelerate a global supply chain of critical raw materials, reagents and consumables in collaboration with our suppliers to enable rapid manufacturing and quality testing. Our vaccine manufacturing facility contains different sized bioreactors for scaling up vaccine production. The various dimensions of their bioreactors came with the need for different ceiling heights for the 2000L bioreactors. There are 4 different cleanroom ceiling heights (14 ft., 12 ft., 10 ft., and 9’6’’ ft.) in this vaccine manufacturing facility for numerous different equipment sizes, operational reasons, and cost savings.
>> Product catalogue